Lab Home | Phone | Search
Center for Nonlinear Studies  Center for Nonlinear Studies
 Home 
 People 
 Current 
 Executive Committee 
 Postdocs 
 Visitors 
 Students 
 Research 
 Publications 
 Conferences 
 Workshops 
 Sponsorship 
 Talks 
 Seminars 
 Postdoc Seminars Archive 
 Quantum Lunch 
 Quantum Lunch Archive 
 P/T Colloquia 
 Archive 
 Ulam Scholar 
 
 Postdoc Nominations 
 Student Requests 
 Student Program 
 Visitor Requests 
 Description 
 Past Visitors 
 Services 
 General 
 
 History of CNLS 
 
 Maps, Directions 
 CNLS Office 
 T-Division 
 LANL 
 
Wednesday, August 21, 2019
10:00 AM - 11:00 AM
CNLS Conference Room (TA-3, Bldg 1690)

Seminar

Analysis of Longitudinal Studies with Treatment by Indication

Mark Glickman
Harvard

It is often of interest in observational studies to measure the causal effect of a treatment on time-to-event outcomes. In a medical setting,observational studies commonly involve patients who initiate medication therapy and others who do not, and the goal is to infer the medication effect on time until recovery or some other time-to-event outcome. A difficulty with such studies is that the notion of a medication initiation time does not exist in the control group. We propose an approach to infer causal effects of an intervention in longitudinal observational studies when the time of treatment assignment is only observed for treated units and where treatment is given by indication. We present a framework for conceptualizing an underlying randomized experiment in this setting based on separating theprocess that governs the time of study arm assignment from the mechanism that determines the assignment. Our approach involves inferring the missing times of assignment followed by estimating treatment effects. This approach allows us to incorporate uncertainty about the missing times of study arm assignment which induces uncertainty in both the selection of the control group and the measurement of time-to-event outcomes for these controls. We demonstrate our approach to study the effects on mortality of inappropriately prescribing phosphodiesterase type 5 inhibitors,a medication contraindicated for groups 2 and 3 pulmonary hypertension, using administrative data from the Veterans Administration health care system.

This is joint work with Reagan Mozer, Bentley University.

Host: Invited Statistical Sciences Seminar Series (CCS-6)